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ABSTRACT: Non-invasive strategies for the analysis of endogenous DNA damage are of interest for the
purpose of monitoring genomic exposure to biologically produced chemicals. We have focused our research
on the biological processing of DNA adducts and how this may impact the observed products in biological
matrixes. Preliminary research has revealed that pyrimidopurinone DNA adducts are subject to enzymatic
oxidation in vitro and in vivo and that base adducts are better substrates for oxidation than the corresponding
2′-deoxynucleosides. We tested the possibility that structurally similar exocyclic base adducts may be
good candidates for enzymatic oxidation in vitro. We investigated the in vitro oxidation of several
endogenously occurring etheno adducts [1,N2-ε-guanine (1,N2-ε-Gua), N2,3-ε-Gua, heptanone-1,N2-ε-Gua,
1,N6-ε-adenine (1,N6-ε-Ade), and 3,N4-ε-cytosine (3,N4-ε-Cyt)] and their corresponding 2′-deoxynucleosides.
Both 1,N2-ε-Gua and heptanone-1,N2-ε-Gua were substrates for enzymatic oxidation in rat liver cytosol;
heteronuclear NMR experiments revealed that oxidation occurred on the imidazole ring of each substrate.
In contrast, the partially or fully saturated pyrimidopurinone analogues [i.e., 5,6-dihydro-M1G and 1,N2-
propanoguanine (PGua)] and their 2′-deoxynucleoside derivatives were not oxidized. The 2′-deoxynucleo-
side adducts, 1,N2-ε-dG and 1,N6-ε-dA, underwent glycolytic cleavage in rat liver cytosol. Together, these
data suggest that multiple exocyclic adducts undergo oxidation and glycolytic cleavage in vitro in rat
liver cytosol, in some instances in succession. These multiple pathways of biotransformation produce an
array of products. Thus, the biotransformation of exocyclic adducts may lead to an additional class of
biomarkers suitable for use in animal and human studies.
Oxidative stress induces cellular damage that contributes
to the onset of multiple diseases, including cancer (1, 2).
Reactive oxygen and nitrogen species produced from the
immune response and during cellular respiration (occasions
of oxidative stress) initiate the modiﬁcation and breakdown
of cellular macromolecules, including polyunsaturated lipids
and DNA. Products of lipid and DNA peroxidation (princi-
pally R, -unsaturated aldehydes) also react with DNA to
produce etheno, propano, and pyrimidopurinone DNA base
adducts. A growing body of evidence suggests that endog-
enous DNA lesions are involved in the development of
cancer (3, 4). Therefore, the quantiﬁcation of DNA adducts
as biomarkers of oxidative stress may be useful for clinical
and population-based risk assessment studies (5, 6). Non-
invasive strategies for the analysis of adducts (i.e., quantify-
ing urinary adduct levels) comprise an attractive approach
for biomarker acquisition and detection, and several labo-
ratories have implemented this strategy (7, 8).
Our laboratory is investigating biological factors (i.e.,
enzymatic oxidation, biliary elimination, etc.) that may limit
the analysis of endogenously produced DNA adducts in
urine. The pyrimidopurinone adduct, M1dG
1 [3-(2′-deoxy-
 -D-erythro-pentofuranosyl)pyrimido[1,2-R]purin-10(3H)-
one], has been the focus of several investigations (9–12).
M1dG is derived from dG in reactions with either MDA
(product of lipid peroxidation and prostaglandin synthesis)
or base propenal (product of DNA peroxidation) (13–19) and
is miscoding in bacteria and humans (20, 21). Genetic and
biochemical evidence suggests that M1dG is released from
DNA by nucleotide excision repair (20, 22), which leads to
the release of the 2′-deoxynucleoside (M1dG) from cells (23).
We recently described the biological processing of free M1dG
and the base adduct, M1G( 9–12). M1dG undergoes a single
oxidation at the 6-position of the pyrimido ring to 6-oxo-
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at the 6-position of the pyrimido ring and then at the
2-position of the imidazole ring to produce 6-oxo-M1G and
2,6-dioxo-M1G, respectively. Comparing the turnover of
M1dG, M1G, and 6-oxo-M1G in rat liver cytosol demon-
strated that the bases were better substrates for oxidation than
the 2′-deoxynucleoside (∼5-fold).
Although no DNA glycosylases have been implicated in
the release of M1G from DNA, several structurally similar
etheno adducts (1,N2-ε-Gua, N2,3-ε-Gua, 1,N6-ε-Ade, and
3,N4-ε-Cyt) are reported substrates for DNA glycosylases
(24–28). Due to the higher apparent rate of turnover of the
M1G bases, and the structural similarity of etheno adducts,
we hypothesized that etheno DNA base adducts would be
likely to undergo oxidation, with the imidazole ring being a
probable target for oxidation. In addition, we investigated
several analogues of M1dG to probe for structural require-
ments leading to the oxidation of exocyclic adducts.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents. All chemicals were obtained
from commercial sources and used as received. Solvents were
of HPLC grade purity or higher. M1dG (29), 6-oxo-M1dG
(12), 5,6-dihydro-M1dG (30), PdG (31), 1,N2-ε-Gua (32),
N2,3-ε-Gua (32), heptanone-1,N2-ε-dG (33), 1,N6-ε-Ade (34),
and 3,N4-ε-dC (35) were synthesized as previously described.
Liver cytosols were prepared by established methods (36).
Bovine XO from buttermilk was obtained from CalBiochem
(La Jolla, CA). PNP was purchased from Sigma (St. Louis,
MO). HPLC separations were performed on a Waters 2695
autosampler and binary pump with a Waters 2487 dual
wavelength UV detector. LC-MS/MS and LC-MSn spectra
were recorded on either ThermoElectron Quantum or LTQ
instruments.
Heptanone-1,N2-ε-Gua Synthesis. Heptanone-1,N2-ε-dG
(12.3 mg, 0.03 mmol) was dissolved in 1 M HCl (4 mL)
and stirred at 65-70 °C for 3 h. The reaction mixture was
neutralized with 1 N NaOH and lyophilized. The resulting
solid was dissolved in DMSO and puriﬁed by HPLC to afford
heptanone-1,N2-ε-Gua (4.1 mg, 47% yield) as a white solid.
The purity of the product was judged to be >98% by HPLC:
1H NMR (600 MHz, DMSO-d6) δ 12.39 (br s, 2H), 7.84 (br
s, 1H), 7.07 (s, 1H), 4.10 (s, 2H), 2.55 (t, 2H), 1.49 (m,
2H), 1.25 (m, 4H), 0.85 (t, 3H); positive ESI-MS m/z 288
[M + H]+; MS/MS of m/z 288 (sid ) 10, collision energy,
45 eV) m/z (relative intensity) 288 (12), 260 (8) 190 (100)
152 (4); 13C NMR (150 MHz, DMSO-d6) δ 206.1, 154.3,
151.4, 147.3, 137.4, 117.8, 116.0, 115.7, 70.2, 41.6, 31.3,
23.1, 22.4, 14.3; FAB HRMS m/z calculated for C14H18N5O2
(M + H) 288.1460, found 288.1460.
Chromatography Methods. Method A. Samples were
separated on a Phenomenex Luna C18(2) column (4.6 mm
× 250 mm, 5 µm) equilibrated with 95% solvent A (0.5%
formic acid in H2O) and 5% solvent B (0.5% formic acid in
methanol) at a ﬂow rate of 1 mL/min. The solvent was
programmed as follows: a linear gradient from the starting
solvent to 30% B in 15 min, increasing to 80% B in 0.1
min, isocratic for 5 min, decreasing to 5% B in 0.1 min, and
re-equilibrating under the initial conditions for 5 min. Eluting
compounds were detected by UV absorbance at 285 nm.
Method B. Samples were separated on a Phenomenex Luna
C18(2) column (4.6 mm × 250 mm, 5 µm) equilibrated with
70% solvent A (0.5% formic acid in H2O) and 30% solvent
B (0.5% formic acid in methanol) at a ﬂow rate of 1 mL/
min. The solvent was programmed as follows: a linear
gradient from the starting solvent to 70% B in 20 min,
increasing to 90% B in 0.1 min, isocratic for 5 min,
decreasing to 30% B in 0.1 min, and re-equilibrating under
the initial conditions for 5 min. Eluting compounds were
detected by UV absorbance at 300 nm. Method C. Samples
were separated on a Phenomenex Synergi POLAR-RP
column (2.0 mm × 150 mm, 4 µm) equilibrated with 98%
solvent A (0.5% formic acid in H2O) and 2% solvent B (0.5%
formic acid in methanol) at a ﬂow rate of 0.3 mL/min. The
solvent was programmed as follows: a linear gradient from
the starting solvent to 40% B in 10 min, holding at 40% B
for 3 min, decreasing to 2% B in 0.1 min, and holding under
the initial conditions for 7 min. Eluting compounds were
detected by UV absorbance at 254 and 275 nm. Method D.
Samples were separated on a Phenomenex Luna C18(2)
column (4.6 mm × 250 mm, 5 µm) equilibrated with 90%
solvent A (0.5% formic acid in H2O) and 10% solvent B
(0.5% formic acid in methanol) at a ﬂow rate of 1.0 mL/
min. The solvent was programmed as follows: a linear
gradient from the starting solvent to 20% B in 10 min,
isocratic at 20% B for 10 min, increasing to 85% B in 0.1
min, isocratic at 85% B for 5 min, decreasing to 10% B in
0.1 min, and isocratic under the initial conditions for 5 min.
Eluting compounds were detected by UV absorbance at 254
nm. Method E. Samples were separated on a Phenomenex
Luna Phenyl-Hexyl column (4.6 mm × 250 mm, 5 µm)
equilibrated with 90% solvent A [20 mM ammonium acetate
(pH 7.0) in H2O] and 10% solvent B [20 mM ammonium
acetate (pH 7.0) in methanol] at a ﬂow rate of 1.0 mL/min.
The solvent was programmed as follows: a linear gradient
from the starting solvent to 50% B in 10 min, decreasing to
10% B in 0.1 min, and isocratic under the initial conditions
for 5 min. Eluting compounds were detected by UV
absorbance at 254 and 285 nm.
LiVer Cytosol Incubations. The following general incuba-
tion conditions were used for all substrates except where
noted below. All sample preparation was performed on ice
at 4 °C. Substrate stock solutions were dissolved in water.
The ﬁnal incubations contained 5 mg/mL rat liver cytosol,
varied concentrations of substrates, 0.4% DMSO, and 0.1
M potassium phosphate (pH 7.4) buffer. All reagents were
equilibrated to 37 °C for 5 min, and the reaction was initiated
by the addition of substrate. Reactions were terminated by
adding 0.5 mL of ice-cold ethanol, and the mixtures were
vigorously mixed and extracted twice with 2 volumes of
CHCl3. The extracts were pooled, evaporated under nitrogen,
and reconstituted in 0.1 M potassium phosphate (pH 7.4).
All reactions were performed in triplicate. Vmax/KM and IC50
values were calculated with Prism (version 4.0c) using
nonlinear regression one-site binding and one-site competi-
tion models, respectively.
1,N2-ε-Gua and N2,3-ε-Gua stock solutions were dis-
solved in 0.1 M NaOH; all incubations were conducted
in 0.8 M potassium phosphate (pH 7.6), and extracted
samples were dissolved in 0.1 M NaOH. 1,N2-ε-Gua, 1,N2-
ε-dG, and N2,3-ε-Gua were analyzed by chromatography
method A. Heptanone-1,N2-ε-dG and heptanone-1,N2-ε-
Gua stock solutions were dissolved in DMSO; all incuba-
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extracted samples were dissolved in methanol. Heptanone-
1,N2-ε-dG and heptanone-1,N2-ε-Gua samples were ana-
lyzed by chromatography method B. 1,N6-ε-dA incubations
were also conducted in 0.1 M Tris-HCl buffer (pH 7.4).
1,N6-ε-dA and 1,N6-ε-Ade were analyzed by method C.
3,N4-ε-dC, 3,N4-ε-Cyt, 5,6-dihydro-M1dG, 5,6-dihydro-
M1G, PdG, PGua, γ-OH-PdG, and R-OH-PdG reactions
were terminated with ice-cold methanol, and the mixtures
were vigorously mixed and centrifuged at 200000g for
30 min. Supernatants were removed and analyzed directly
by chromatography method D, except for 3,N4-ε-dC and
3,N4-ε-Cyt, which were analyzed by method E.
Incubations of 1,N2-ε-Gua with Puriﬁed XO. All sample
preparation was performed on ice at 4 °C. The ﬁnal
incubations for the kinetic determinations contained 0.10 unit
of XO/mL (CalBiochem), varied concentrations of 1,N2-ε-
Gua, and 0.4% DMSO in 0.8 M potassium phosphate (pH
7.6). Reagents were equilibrated to 37 °C for 5 min, and the
reaction was initiated by the addition of the substrate.
Reactions were terminated by adding 0.5 mL of ice-cold
ethanol, and mixtures were vigorously mixed and extracted
twice with 2 volumes of CHCl3. The extracts were evaporated
under nitrogen and reconstituted in 0.1 M NaOH. Samples
were analyzed by chromatography method A. Samples from
the kinetic determinations were quantiﬁed in reference to a
standard curve prepared by spiking known concentrations
of 1,N2-ε-Gua into 0.10 unit/mL XO solutions, followed
immediately by termination, extraction, and analysis as
outlined above. All incubations and standards were per-
formed in triplicate.
Incubations of 1,N6-ε-dA and dIno with Puriﬁed Human
PNP. All sample preparation was performed on ice at 4 °C.
The speciﬁc activity of PNP was 18 units/mg. The ﬁnal
incubations for the kinetic determinations contained PNP (1.5
units/mL for 1,N6-ε-Ade and 0.025 unit/mL for dIno reac-
tions), varied concentrations of either 1,N6-ε-Ade or dIno,
and 0.8 M potassium phosphate (pH 7.6). Reagents were
equilibrated to 37 °C for 5 min, and the reaction was initiated
by the addition of substrate. Reactions were terminated with
ice-cold ethanol, and mixtures were vigorously mixed,
followed by the addition of 1 volume of CHCl3. Samples
were evaporated under nitrogen, reconstituted in 0.1 M
potassium phosphate (pH 7.4), and analyzed by chromatog-
raphy method C, with the ﬂow rate adjusted to 1.0 mL/min.
All incubations were prepared in triplicate.
LC-MS/MS Analysis. Following sample workup as noted
above, selected samples were analyzed by LC-MS/MS
analysis. The previously described chromatography methods
(see above) were adapted to lower ﬂow rates (0.3 mL/min)
for sample analysis. Eluting compounds were analyzed on
either ThermoElectron LTQ or Quantum instruments. Posi-
tive ion ESI LC-MS/MS or LC-MSn was performed with
the following general parameters: spray voltage, 4.2 eV;
capillary temperature, 275 °C; sheath gas, 60 psi; source CID
off; and varied collision energies.
Biochemical Synthesis of the 1,N2-ε-Gua Metabolite [1H-
imidazo[1,2-a]purine-2,9(3H,5H)-dione]. 1,N2-ε-Gua (2 mg)
was incubated with 5 mL of concentrated rat liver cytosol
(13.6 mg/mL) and allowed to proceed to completion. The
reaction mix was centrifuged at 10000g for 15 min to pellet
protein, and the supernatant was injected directly onto the
HPLC system. Fractions corresponding to the 1,N2-ε-Gua
metabolite were pooled, evaporated under reduced pressure,
and dissolved in DMSO-d6 for NMR analysis. Puriﬁed 2-oxo-
ε-Gua was analyzed by HRMS to probe for the calculated
m/z of C7H6N5O2 (M + H) of 191.1469 (found 191.0443).
Biochemical Synthesis of the Heptanone-1,N2-ε-Gua Me-
tabolite [7-(2-oxoheptyl)-1H-imidazo[1,2-a]purine-2,9(3H,5H)-
dione]. Heptanone-1,N2-ε-Gua (1 mg) was reacted in 30 mL
of concentrated gerbil liver cytosol and allowed to proceed
to completion. Fifteen milliliters of ethanol was added to
the reaction mix and centrifuged at 10000g for 15 min to
precipitate protein. An additional 15 mL of ethanol was
added to the supernatant, and the mixture was extracted twice
with 50 mL of chloroform. The organic layers were pooled
and evaporated under reduced pressure. The remaining
residue was redissolved in methanol and directly injected
onto the HPLC system. Fractions corresponding to the
heptanone-1,N2-ε-Gua metabolite were collected, evaporated
under reduced pressure, and dissolved in DMSO-d6 for NMR
analysis. Puriﬁed 2-oxoheptanone-ε-Gua was analyzed by
HRMS to probe for the calculated m/z of C14H17N5O3 (M +
H) of 303.3165 (found 303.1331).
NMR Analysis of 1,N2-ε-Gua and Heptanone-1,N2-ε-Gua
Metabolites. NMR experiments were conducted using a 14.0
T Bruker magnet equipped with a Bruker AV-III console
operating at 600.13 MHz. All spectra were acquired in 3
mm NMR tubes using a Bruker 5 mm TCI cryogenically
cooled NMR probe. Chemical shifts were referenced inter-
nally to DMSO (0.49 ppm), which also served as the 2H
lock solvent. For one-dimensional (1D) 1H NMR, typical
experimental conditions included 32K data points, a sweep
width of 13 ppm, a recycle delay of 1.5 s, and 32-256 scans
depending on sample concentration. For two-dimensional
(2D) 1H-1H COSY, experimental conditions included 2048
× 512 data matrix, a sweep width of 13 ppm, a recycle delay
of 1.5 s, and four scans per increment. The data were
processed using a squared sine bell window function,
symmetrized, and displayed in magnitude mode. Multiplicity-
edited heteronuclear single-quantum coherence (HSQC)
experiments were conducted using a 1024 × 256 data matrix,
a J(C-H) value of 145 Hz which resulted in a multiplicity
selection delay of 34 ms, a recycle delay of 1.5 s, and 16
scans per increment along with GARP decoupling on 13C
during the acquisition time (150 ms). The data were
processed using a π/2 shifted squared sine window function
and displayed with CH/CH3 signals phased positive and CH2
signals phased negative. J1(C-H) ﬁltered HMBC experi-
ments were conducted using a 2048 × 256 data matrix, a
J(C-H) value of 9 Hz for detection of long-range couplings
resulting in an evolution delay of 55 ms, a J1(C-H) ﬁlter
delay of 145 Hz (34 ms) for the suppression of one-bond
couplings, a recycle delay of 1.5 s, and 128 scans per
increment. The HMBC data were processed using a π/2
shifted squared sine window function and displayed in
magnitude mode.
RESULTS
Oxidation of 1,N2-ε-Gua in Rat LiVer Cytosol. 1,N2-ε-Gua
is released from DNA by the alkylpurine-DNA-N-glycosylase
in mammalian cells (25, 27). The base adduct 1,N2-ε-Gua is
structurally very similar to the pyrimidopurinone adduct,
802 Biochemistry, Vol. 48, No. 4, 2009 Knutson et al.M1G (Figure 1), which is a substrate for enzymatic oxidation
in vitro and in vivo (9). To investigate whether 1,N2-ε-Gua
was also a substrate for oxidation, we performed in vitro
experiments using rat liver cytosol. Proﬁling the reaction
extracts by HPLC with UV detection demonstrated a time-
dependent decrease in the level of N2-ε-Gua and the
appearance of a new peak eluting shortly after it. Positive
ion ESI LC-MS analysis of the later eluting peak revealed
an m/z of 192.1, which suggested the incorporation of a single
oxygen atom. No additional products were observed in the
MS or UV spectra. MSn experiments were carried out on
the putative metabolite, which displayed fragmentation
patterns similar to those of 1,N2-ε-Gua, except for the
addition of 16 amu, which was apparent with the base peak
and with some fragments (Figure 2). 1,N2-ε-Gua metabolite
production was inhibited by allopurinol, an inhibitor of
xanthine oxidoreductase (XOR), but not by menadione or
raloxifene, each an inhibitor of aldehyde oxidase (AO), which
suggested the involvement of XOR in the oxidation of 1,N2-
ε-Gua (Figure 2).
Further investigation into the turnover of 1,N2-ε-Gua in
rat liver cytosol revealed a KM of 84 µM and a Vmax of 105
pmol min-1 mg-1 (Vmax/KM ) 0.005 min-1 mg-1) (Table 1).
These calculated values are very close to what was observed
for M1G and 6-oxo-M1G oxidation in rat liver cytosol (9).
IC50 determinations with allopurinol on 1,N2-ε-Gua oxidation
revealed complete inhibition of metabolite production at
saturating concentrations of allopurinol in rat liver cytosol
(IC50 of 1.4 µM) (Figure 2).
Oxidation of 1,N2-ε-Gua with Puriﬁed XO. The complete
inhibition of 1,N2-ε-Gua oxidation by allopurinol suggested
XOR was the only enzyme involved in the oxidation of 1,N2-
ε-Gua. In vitro oxidation of 1,N2-ε-Gua was performed using
puriﬁed bovine xanthine oxidase (XO). XO readily consumed
1,N2-ε-Gua, demonstrating a KM of 108 µM and a Vmax of
10.1 µmol min-1 (mg of XO)-1 (Figure 3).
Structural Characterization of the 1,N2-ε-Gua Metabolite.
To identify the product of 1,N2-ε-Gua oxidation in rat liver
cytosol, we biochemically synthesized the metabolite with
concentrated rat liver cytosol and puriﬁed the product by
fraction collection from a HPLC system. The product was
concentrated and dissolved in DMSO-d6 for NMR analysis.
Comparison of the 1H NMR spectra for 1,N2-ε-Gua and the
metabolite revealed an absence of the singlet corresponding
to H2 (7.8 ppm) from the imidazole ring, while two
correlated doublets remained from the etheno ring for H7
(d, 1H, 7.6 ppm) and H6 (d, 1H, 7.4 ppm) (Figure 4) (37).
This was conﬁrmed by the HSQC spectrum, which demon-
strated the metabolite contained only CH protons (Figure
S1 of the Supporting Information). If oxidation had occurred
on the etheno ring, the carbon adjacent to the site of oxidation
would have been reduced to CH2. HMBC analysis revealed
three-bond couplings for H7 and H6 to C4a (145 ppm),
FIGURE 1: Structures of endogenously formed exocyclic DNA base
adducts and structural analogues of M1dG.
FIGURE 2: In vitro oxidation of 1,N2-ε-Gua in rat liver cytosol. (A)
MSn fragmentation of 1,N2-ε-Gua (m/z 176). (B) MSn fragmentation
of the 1,N2-ε-Gua metabolite (m/z 192). (C) Effect of inhibitors of
XOR (allopurinol) and AO (menadione and raloxifene) on the
consumption of 1,N2-ε-Gua in rat liver cytosol. (D) IC50 determi-
nation for the inhibition of the 1,N2-ε-Gua metabolite in rat livery
cytosol using 1,N2-ε-Gua (84 µM) as a substrate. IC50 values were
determined on the basis of 1,N2-ε-Gua metabolite inhibition with
increasing concentrations of allopurinol in rat liver cytosol (IC50
) 1.4 µM).
Table 1: Km and Vmax Values for the Oxidation of 1,N2-ε-Gua, M1G,
6-oxo-M1G, and M1dG in Rat Liver Cytosol
substrate KM (µM) Vmax (nmol min-1 mg-1) Vmax/KM (min-1 mg-1)
1,N2-ε-Gua 84 105 0.005
M1G
a 105 126 0.005
6-oxo-M1G
a 210 257 0.005
M1dG
b 370 104 0.001
a Values taken from ref 9.
b Values taken from ref 12.
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but on the imidazole ring yielding 2-oxo-ε-Gua (Figure 4).
Glycolytic CleaVage of 1,N2-ε-dG in Rat LiVer Cytosol.
The observed oxidation of 1,N2-ε-Gua in rat liver cytosol
led us to investigate the stability of the 2′-deoxynucleoside,
1,N2-ε-dG. We were curious to know if oxidation would
occur on the imidazole ring of the etheno adduct contain-
ing 2′-deoxyribose. Incubation conditions identical to those
of 1,N2-ε-Gua studies were used with 1,N2-ε-dG in rat liver
cytosol. The 2′-deoxynucleoside adduct did not undergo
oxidation. However, LC-UV and LC-MS analysis of the
reaction mixture indicated 1,N2-ε-dG was consumed over
time, producing a new chromatographic peak eluting with
an identical retention time and mass spectrum for the base,
1,N2-ε-Gua. Furthermore, the newly produced 1,N2-ε-Gua
was converted to the oxidized product, 2-oxo-ε-Gua. There
was no evidence to support direct oxidation of the 2′-
deoxynucleoside. These data suggested 1,N2-ε-dG was
subject to glycolytic cleavage in rat liver cytosol, and the
product of this conversion was subsequently oxidized
(Figure 4).
Glycolytic cleavage was not observed with M1dG either
in vitro in rat liver cytosol or in vivo in the rat (11, 12).
Results with 1,N2-ε-dG suggest the involvement of an
additional pathway for exocyclic adduct biotransformation.
Purine nucleoside phosphorylase (PNP) is an enzyme
involved in purine catabolism as part of the purine salvage
pathway. PNP carries out the glycolytic cleavage of 6-ox-
opurine nucleosides and 2′-deoxynucleosides [guanosine,
inosine, dG, and 2′-deoxyinosine (dIno)] to their correspond-
ing bases (Gua and hypoxanthine). The enzyme uses
inorganic phosphate (H2PO4
-) as a cosubstrate and produces
(2′-deoxy)ribose-1-phosphate in addition to the base. PNP
is expressed in rat liver (38, 39). The observed cleavage of
1,N2-ε-dG to 1,N2-ε-Gua suggests the involvement of PNP
in rat liver cytosol.
Oxidation of Heptanone-1,N2-ε-Gua in Rat LiVer Cytosol.
Two exocyclic base adducts (6-oxo-M1G and 1,N2-ε-Gua)
undergo enzymatic oxidation on the imidazole ring. In both
instances, the presence of the 2′-deoxyribose moiety on the
imidazole portion of the base retards this oxidation. As a
corollary, we were curious to know what effects etheno ring
substituents would have on imidazole oxidation. To address
this question, we investigated the endogenously produced
heptanone-1,N2-ε-dG, which contains a 2-oxoheptyl side
chain extending off of C7 on the etheno ring (Figure 1) (33).
We performed in vitro experiments using rat liver cytosol
with heptanone-1,N2-ε-dG and its corresponding base, hep-
tanone-1,N2-ε-Gua. The 2′-deoxynucleoside was stable in rat
liver cytosol and was a substrate for neither oxidation nor
glycolytic cleavage. However, the base adduct heptanone-
1,N2-ε-Gua was oxidized. Proﬁling the reaction mixtures by
LC-MS/MS revealed a new peak eluting shortly after
heptanone-1,N2-ε-Gua. MSn experiments were conducted
with the putative heptanone-1,N2-ε-Gua metabolite, which
displayed fragmentation patterns similar to those of hep-
tanone-1,N2-ε-Gua, except for the addition of 16 amu, which
was apparent with the base peak and with some fragments
(Figure 5). The use of chemical inhibitors suggested the
involvement of XOR because co-incubation with allopurinol
inhibited oxidation, but co-incubation with either menadione
or raloxifene did not (Figure 5). Limitations in analyte
solubility precluded concentration-dependent kinetic deter-
minations in rat liver cytosol.
Biochemical Synthesis of the Heptanone-1,N2-ε-Gua Me-
tabolite. Heptanone-1,N2-ε-Gua was reacted to completion
in concentrated gerbil liver cytosol, extracted, and puriﬁed
by reverse phase HPLC. HPLC fractions containing the
metabolite were concentrated and dissolved in DMSO-d6 for
analysis by NMR. The HSQC and HMBC experiments
enabled identiﬁcation of the metabolite as 2-oxoheptanone-
ε-Gua (Figure 6). H6 (s, 1H, 7.1 ppm, C6 at 116 ppm) was
evident in the HSQC spectrum and showed a two-bond
correlation to C7 (119 ppm) and a three-bond correlation to
C4a (146 ppm) in the HMBC spectrum. H1′ (s, 2H, 4.1 ppm,
FIGURE 3: Concentration dependence of 1,N2-ε-Gua oxidation in
puriﬁed XOR. 1,N2-ε-Gua consumption was assessed using XOR
puriﬁed from bovine milk. Kinetic determinations were made in
reference to a standard curve for the consumption of 1,N2-ε-Gua
[KM ) 108 µM, and Vmax ) 10.1 µmol min-1 (mg of XOR)-1].
FIGURE 4: Structural determination of the 1,N2-ε-Gua metabolite
as 2-oxo-1,N2-ε-Gua. (A) HMBC spectrum of the 1,N2-ε-Gua
metabolite from rat liver cytosol conﬁrming the structure as 2-oxo-
ε-Gua. (B) 1,N2-ε-dG undergoes glycolytic cleavage to 1,N2-ε-Gua
in rat liver cytosol, which is then oxidized by XOR to 2-oxo-ε-
Gua.
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exhibited two-bond correlations to C7 (119 ppm) and C2′
(206 ppm) and a three-bond coupling to C6 (116 ppm) in
the HMBC spectrum. The three-bond coupling from H6 to
C1′ was not observed, however. Direct comparison of the
metabolite spectra to the heptanone-1,N2-ε-Gua spectra was
inconclusive. Several additional chemical shifts were ob-
served in the starting material, which were an artifact of the
sample workup, and attributed to the equilibrium between
heptanone-1,N2-ε-Gua and the hemiketal (33).
InVestigation of N2,3-ε-Gua, 3,N4-ε-dC, 3,N4-ε-Cyt, 1,N6-
ε-dA, and 1,N6-ε-Ade Stability. Several exocyclic adducts
of dG have been characterized as undergoing oxidation in
rat liver cytosol. The 1,N2-ε-Gua isomer, N2,3-ε-Gua, is
derived from lipid peroxidation and is a substrate for repair
by DNA glycosylase (24, 40). The exocyclic etheno ring of
N2,3-ε-Gua is positioned more proximal to the imidazole ring
of guanine and represents a greater departure from the M1G
template. Incubation of N2,3-ε-Gua in either rat liver cytosol
or puriﬁed bovine XO did not result in oxidative metabolism;
thus, the adduct was stable to enzymatic oxidation.
3,N4-ε-dC and 1,N6-ε-dA are etheno adducts of dC and
dA (Figure 1), respectively, with proposed routes of endog-
enous formation (41, 42). 3,N4-ε-dC and 1,N6-ε-dA are
released from DNA by glycosylase action as the correspond-
ing base adducts, 3,N4-ε-Cyt (26, 28) and 1,N6-ε-Ade (25, 28),
respectively. The exocyclic etheno rings for these molecules
are structurally similar and contain a heterocyclic imine
extending from a quaternary carbon on the base, which is a
pyrimidine in the case of 3,N4-ε-Cyt and purine for 1,N6-ε-
Ade. Each base adduct was investigated for enzymatic
oxidation in rat liver cytosol, but neither was found to be
oxidized.
The corresponding 2′-deoxynucleoside adducts 3,N4-ε-dC
and 1,N6-ε-dA were also investigated for their stability in
rat liver cytosol. The reaction mixtures were proﬁled by
positive ion ESI LC-MS/MS, and neither of these adducts
was found to be oxidized in vitro. However, 1,N6-ε-dA
underwent a time-dependent decrease in total peak area, with
a corresponding increase of an early eluting peak, which
displayed an ion at m/z 162.1. The appearance of the ion at
m/z 162.1 was not detected in control incubations. The early
eluting peak corresponded to the protonated molecular ion
for the base (1,N6-ε-Ade), suggesting that 1,N6-ε-dA under-
went glycolytic cleavage. This product also cochromato-
graphed when the incubation extract was spiked with an
authentic 1,N6-ε-Ade standard. Identical observations were
made using 1,N6-ε-adenosine in incubations with rat liver
cytosol.
To investigate the role of PNP, which uses H2PO4
- as a
cosubstrate in the glycolytic cleavage of 1,N6-ε-dA, we
performed rat liver cytosol incubations using either potassium
phosphate or Tris-HCl buffers. In the absence of inorganic
phosphate, the production of 1,N6-ε-Ade was diminished
(Figure 7). 1,N6-ε-dA was also incubated in reactions with
puriﬁed PNP from human blood using potassium phosphate
buffer. Glycolytic cleavage of 1,N6-ε-dA was dependent on
protein concentration and incubation time. Determinations
of Vmax/KM for 1,N6-ε-dA turnover in puriﬁed PNP were
extrapolated from the linear portion of the V versus S plot.
Turnover of dIno (a natural substrate for PNP) under similar
reaction conditions revealed that the efﬁciency of turnover
FIGURE 5: In vitro oxidation of heptanone-1,N2-ε-Gua in rat liver
cytosol. (A) MSn fragmentation of heptanone-1,N2-ε-Gua (m/z 288).
(B) MSn fragmentation of the heptanone-1,N2-ε-Gua metabolite (m/z
304). (C) Effect of inhibitors of XOR (allopurinol) and AO
(menadione and raloxifene) on the consumption of heptanone-1,N2-
ε-Gua in rat liver cytosol.
FIGURE 6: Structural determination of the heptanone-1,N2-ε-Gua
metabolite as 2-oxoheptanone-1,N2-ε-Gua. (A) Overlay of the
HSQC and HMBC spectra for the biochemically synthesized
heptanone-1,N2-ε-Gua metabolite, which conﬁrmed the structure
as 2-oxoheptanone-ε-Gua. (B) Heptanone-1,N2-ε-Gua is oxidized
to 2-oxoheptanone-ε-Gua in liver cytosol by XOR.
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that for 1,N6-ε-dA (0.3 min-1).
InVestigation of M1dG Analogues in Rat LiVer Cytosol.
To lend further insight into the structural requirements for
the oxidation and glycolytic cleavage of exocyclic adducts
in rat liver cytosol, we investigated the stability of several
pyrimidopurinone-dG analogues of M1dG and M1G (Figure
1). The partially reduced pyrimido analogues 5,6-dihydro-
M1dG and 5,6-dihydro-M1G and fully reduced analogues
PdG and PGua have previously been used to mimic the
biological activity of M1dG in several genetic and biochemi-
cal investigations (22, 30). γ-OH-PdG and R-OH-PdG are
endogenous adducts produced from reactions of acrolein with
dG (43). These dG modiﬁcations impart different electronic
and structural features on the exocyclic ring. For example,
the pyrimido ring is planar and aromatic, whereas the
propano ring is puckered and unconjugated. Members of this
series of dG adducts are approximately the same size as the
pyrimidopurinone adducts, so the exocyclic propano ring
should not preclude access to the active sites of XOR, AO,
or PNP. All investigations in rat liver cytosol with the 2′-
deoxynucleoside structural analogues revealed no indication
of either oxidation or glycolytic cleavage. Additionally, none
of the base adducts was oxidized.
DISCUSSION
Non-invasive analysis of endogenously occurring DNA
damage is of interest for use in clinical and animal studies.
We propose that it is important to consider the possibility
of biological processing during the development of analytical
methods designed to evaluate endogenous levels of adducts.
Although the elimination of DNA adducts in the urine is
typically attributed to repair-dependent removal from DNA,
it is important to consider that multiple factors may contribute
to or limit their steady-state elimination rates (7, 44, 45).
The contribution of modiﬁed DNA bases in the nucleotide
pool, the release of adducts from apoptotic and necrotic cells,
and the introduction of lesions from dietary intake may
contribute to the levels of DNA base adducts in biological
matrixes. However, these sources have not been fully
evaluated. Additionally, the biliary elimination of adducts
into the feces reduces the amount of adducts available for
detection from urine samples (10). Independent of the route
of formation in vivo, the metabolic processing of adducts as
they pass through the circulatory system may limit their direct
detection in biological matrixes.
This study was designed to determine structural features
of exocyclic adducts that leads to oxidation. We focused our
investigation on small changes in the pyrimido ring of M1dG
that imparted alterations to size and conjugation as well as
the addition of substituents. In total, our ﬁndings demonstrate
that the enzymatic oxidation of DNA base adducts can occur
either on the exocyclic ring, as seen with M1dG and M1G,
or on the imidazole ring, as seen with 6-oxo-M1G, 1,N2-ε-
Gua, and heptanone-1,N2-ε-Gua. Both 2′-deoxynucleosides
and bases are subject to oxidation, with the base adducts
being better substrates. When attached to the base, 2′-
deoxyribose appears to prohibit oxidation on the imidazole
ring. Additionally, biological processing is not limited to
oxidation, as 2′-deoxynucleosides and nucleosides may also
undergo glycolytic cleavage to the corresponding base
adducts. We did not observe oxidation with dA, Ade, dC,
or Cyt etheno adducts, but this does not preclude others
derivatives of dA, Ade, dC, or Cyt from biotransformation.
The absence of oxidative metabolism for 1,N6-ε-Ade and
3,N4-ε-Cyt is noteworthy since both adducts have been
implicated as substrates for oxidative DNA repair. The DNA
repair enzyme AlkB utilizes non-heme iron, oxygen, and
R-ketoglutarate to repair alkyl DNA damage; the human
ortholog, hABH2, likely acts by a similar mechanism (46, 47).
AlkB oxidizes both 1,N6-ε-Ade and 3,N4-ε-Cyt to generate
epoxide and glyoxal intermediates prior to complete removal
of the etheno bridge. This oxidative mechanism is a departure
from the oxidation carried out by AO and XOR, which
incorporate water (not molecular oxygen) from the molyb-
dopterin active site (48).
FIGURE 7: Conversion of 1,N6-ε-dA to 1,N6-ε-Ade in rat liver
cytosol. (A) Effect of either potassium phosphate or Tris-HCl buffer
on the conversion of 1,N6-ε-dA (100 µM) to 1,N6-ε-Ade in rat liver
cytosol. (B) Conversion of 1,N6-ε-dA to 1,N6-ε-Ade carried out by
PNP.
FIGURE 8: Structures of stretched-out 6-oxopurine analogues
synthesized by Leonard et al. (51) and their conversion to oxidized
products by XO from bovine milk.
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of XOR and AO substrate speciﬁcity and inhibition (49–54).
In general, substrates are nitrogen-containing heterocycles,
and the enzyme-mediated oxidation is targeted to electro-
positive carbons, which lie adjacent to ring nitrogens (54).
Our observations with exocyclic adducts are consistent with
these observations.
In a series of biochemical experiments, Leonard et
al. (51, 52) demonstrated XOR-mediated oxidation with
several modiﬁed purine structures that are structurally
similar to the pyrimido and etheno adducts of dG (Gua)
and dA (Ade) (Figure 8). Inserting a benzene ring between
the imidazole and pyrimidine rings of 6-oxopurine (hy-
poxanthine) yielded several “stretched-out” purine ana-
logues. lin-Benzohypoxanthine is similar to M1G; how-
ever, for M1G, the benzene ring is attached to the
pyrimidine opposite the imidazole ring, not beween the
pyrimidine and imidazole ring. Using bovine XOR,
Leonard et al. demonstrated successive oxidations of lin-
benzohypoxanthine to uric acid-like molecules. This is
analogous to what was previously observed with M1G( 9).
Interestingly, Leonard et al. also observed successive
oxidations with the ribonucleoside, lin-benzoinosine. In
our investigations, oxidation on the imidazole ring did not
occur with any 2′-deoxynucleoside-containing base adducts.
Thus far, all characterized oxidation products of exo-
cyclic adducts occur on imine carbons of either the
exocyclic or imidazole rings. Reduction of the 5,6-double
bond on the pyrimido ring of M1dG (M1G) yields a
saturated carbon at the 6-position, and fully reducing the
exocyclic ring produces a fully saturated propano ring.
Neither of these analogues of M1dG (M1G) underwent
oxidation in rat liver cytosol. Krenitsky et al. demonstrated
that purine is oxidized by XOR ﬁrst at the 6-position and
then successively at the 2- and 8-positions. However, AO
oxidizes purine only at the 8-positition on the imidazole
carbon (49). The analogous position on the M1G analogues
is the 2-position, which was not a target for oxidation by
AO or XOR. However, the imidazole ring of 1,N2-ε-Gua
was targeted for oxidation by XOR. The exocyclic ring
of 1,N2-ε-Gua is only one carbon larger than M1G. This
would imply that the XOR active site cannot accommodate
this small increase, and this cannot be overcome by
reducing the nonplanar character of the pyrimido ring.
The effect of substitutions on the exocyclic ring of propano
and etheno dG adducts was investigated. PdG adducts with
hydroxyl substituents on the exocyclic ring did not undergo
biological processing, although the base adducts were not
investigated. The addition of an alkyl substituent on the
exocyclic ring of heptanone-1,N2-ε-Gua did inﬂuence oxida-
tion, however. Heptanone-1,N2-ε-Gua underwent oxidation
at the 2-position of the imidazole ring, whereas the 2′-
deoxynucleoside was not modiﬁed. Heptanone-1,N2-ε-dG did
not undergo glycolytic cleavage as seen with the unsubsti-
tuted 1,N2-ε-dG. Several recent reports from Blair and
colleagues suggest substituted etheno adducts of dA, dC, and
dG comprise a major class of endogenous adducts derived
from products of lipid peroxidation (4, 33, 55–58). The repair
products of these unsubstituted adducts are unknown;
therefore, the biological processing of heptanone-1,N2-ε-Gua
may be of interest when monitoring its levels from biological
matrixes. Additionally, several purine-based therapeutics
(aciclovir, penciclovir, and zaleplon) and other substituted
purine molecules are substrates for oxidation by AO and
XOR (49, 59, 60). Thus, it will be interesting to elucidate
the biochemical processing of other substituted etheno
adducts.
PNP is a central enzyme in the purine salvage pathway.
The enzyme functions to both synthesize and cleave nucleo-
sides and 2′-deoxynucleosides, but the cleavage reaction
(phosphorolysis) is generally favored in vivo. In general,
substrates for the mammalian enzyme are 6-oxopurines and
their corresponding nucleosides and 2′-deoxynucleosides,
although PNP is typically less active toward 6-aminopurines.
Our observation of 1,N6-ε-dA, which lacks the 6-oxo group,
as a moderate substrate for phosphorolysis is of interest.
Modiﬁcation of adenosine nucleosides with alkyl substituents
on the purine ring has previously been shown to increase
the rate of phosphorolysis (39).
1,N2-ε-dG and 1,N6-ε-dA underwent glycolytic cleavage
to base adducts 1,N2-ε-Gua and 1,N6-ε-Ade, respectively, in
rat liver cytosol. Both of these base adducts have been
detected in urine from humans and rats (8, 61). The
elimination of these adducts in urine has generally been
attributed to their removal from DNA as base adducts.
Interestingly, 1,N6-ε-dA has also been detected in rat urine
(7). On the basis of our results, 1,N6-ε-Ade may be the best
target for quantiﬁcation in urine samples. This hypothesis is
also supported by a previous in vivo study on the metabolism
and elimination of 14C-labeled 1,N6-ε-adenosine (62), which
suggested a signiﬁcant percentage of exogenously adminis-
tered 1,N6-ε-adenosine was eliminated in urine as the free
base, 1,N6-ε-Ade.
Since endogenously formed exocyclic adducts are all
modiﬁcations of purine and pyrimidine structures, we
targeted our investigation to the cytosolic components of
rat liver where XOR and AO are located. It is possible
that other enzymes may catalyze the biotransformation of
exocyclic adducts. CYPs and UDP-glucuronosyl trans-
ferases (components of the microsomal fraction of rat
liver) may have a role in biotransformation. Our results
with the propano analogues suggest they are stable in vitro
in rat liver cytosol. Propano adducts derived from cro-
tonaldehyde and 4-hydroxy-2-nonenal also have alkyl
substituents extended from the exocyclic ring, which may
be targeted by different enzymes and alternate routes of
biological processing.
Understanding the in vitro routes of biological processing
should help guide the development of analytical methodolo-
gies for the detection of endogenous adducts. Several
exocyclic adducts have been characterized as good substrates
for oxidation in vitro. The end products of biological
processing may therefore be reliable targets for assessing
the formation of endogenous adducts from biological ma-
trixes in vivo.
SUPPORTING INFORMATION AVAILABLE
HSQC spectrum for the 2-oxo-ε-Gua metabolite. This
material is available free of charge via the Internet at http://
pubs.acs.org.
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